Global Biosimilars Market 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Region: Trend Forecast and Growth Opportunity

November 2021 | 180 pages | ID: G0C9A55CDA23EN
GMD Research

Abstracts

Global biosimilars market will reach $113.25 billion by 2030, growing by 25.7% annually over 2020-2030 driven by the affordability of biosimilar-based treatment, rising incidence of chronic diseases due to aging populations, patent expirations of many blockbuster drugs, and better healthcare provisions.

Highlighted with 89 tables and 90 figures, this 180-page report “Global Biosimilars Market 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire global biosimilars market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19).

In-depth qualitative analyses include identification and investigation of the following aspects:

• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces

The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global biosimilars market in every aspect of the classification from perspectives of Product Type, Indication, Manufacturing, End User, and Region.

Based on Product Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.

• Recombinant Non-glycosylated Biosimilars
• Insulin
• Recombinant Human Growth Hormone (rHGH)
• Granulocyte Colony Stimulating Factor
• Interferon
• Recombinant Glycosylated Biosimilars
• Monoclonal Antibodies (mAb)
• Erythropoietin (EPO)
• Follicle Stimulating Hormone
• Recombinant Peptides and Others
• Tumor Necrosis Factor (TNF)-Inhibitor
• Parathyroid Hormone
• Enzymes, Immunomodulators, GnRH Analogs and Others

Based on Indication, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.

• Cancer
• Autoimmune Disease
• Blood Disorder
• Diabetes
• Growth Hormone Deficiency
• Infectious Diseases
• Other Indications

Based on Manufacturing, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.

• Contract Manufacturing
• Inhouse Manufacturing

Based on End User, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.

• Hospitals and Clinics
• Research Institutes
• Other End Users

Geographically, the following regions together with the listed national/local markets are fully investigated:

• North America (U.S., Canada, and Mexico)
• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
• South America (Brazil, Chile, Argentina, Rest of South America)
• MEA (Turkey, Iran, South Africa)

For each aforementioned region and country, detailed analysis and data for annual revenue ($ mn) are available for 2019-2030. The breakdown of all regional markets by country and split of key national markets by Product Type, Indication, and End User over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Key Players (this may not be a complete list and extra companies can be added upon request):

AMEGA Biotech S.A.

Apotex Inc.

Biocon Ltd

Biogen Inc.

Boehringer Ingelheim

Celltrion, Inc.

Dr. Reddy’s Laboratories Ltd.

Eli Lilly and Company

Intas Pharmaceuticals Ltd.

LG Chem, Ltd.

Merck and Co. Inc.

Mylan N.V.

Pfizer Inc.

Samsung Biologics Co., Ltd.

Sandoz International GmbH

STADA Arzneimittel AG

Teva Pharmaceutical Industries Ltd.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Contents

1 INTRODUCTION

1.1 Industry Definition and Research Scope
  1.1.1 Industry Definition
  1.1.2 Research Scope
1.2 Research Methodology
  1.2.1 Overview of Market Research Methodology
  1.2.2 Market Assumption
  1.2.3 Secondary Data
  1.2.4 Primary Data
  1.2.5 Data Filtration and Model Design
  1.2.6 Market Size/Share Estimation
  1.2.7 Research Limitations
1.3 Executive Summary

2 MARKET OVERVIEW AND DYNAMICS

2.1 Market Size and Forecast
  2.1.1 Impact of COVID-19 on World Economy
  2.1.2 Impact of COVID-19 on the Market
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Fiver Forces Analysis

3 SEGMENTATION OF GLOBAL MARKET BY PRODUCT TYPE

3.1 Market Overview by Product Type
3.2 Recombinant Non-glycosylated Biosimilars
  3.2.1 Insulin
  3.2.2 Recombinant Human Growth Hormone (rHGH)
  3.2.3 Granulocyte Colony Stimulating Factor
  3.2.4 Interferon
3.3 Recombinant Glycosylated Biosimilars
  3.3.1 Monoclonal Antibodies (mAb)
  3.3.2 Erythropoietin (EPO)
  3.3.3 Follicle Stimulating Hormone
3.4 Recombinant Peptides and Others
  3.4.1 Tumor Necrosis Factor (TNF)-Inhibitor
  3.4.2 Parathyroid Hormone
  3.4.3 Enzymes, Immunomodulators, GnRH Analogs and Others

4 SEGMENTATION OF GLOBAL MARKET BY INDICATION

4.1 Market Overview by Indication
4.2 Cancer
4.3 Autoimmune Disease
4.4 Blood Disorder
4.5 Diabetes
4.6 Growth Hormone Deficiency
4.7 Infectious Diseases
4.8 Other Indications

5 SEGMENTATION OF GLOBAL MARKET BY MANUFACTURING

5.1 Market Overview by Manufacturing
5.2 Contract Manufacturing
5.3 Inhouse Manufacturing

6 SEGMENTATION OF GLOBAL MARKET BY END USER

6.1 Market Overview by End User
6.2 Hospitals and Clinics
6.3 Research Institutes
6.4 Other End Users

7 SEGMENTATION OF GLOBAL MARKET BY REGION

7.1 Geographic Market Overview 2019-2030
7.2 North America Market 2019-2030 by Country
  7.2.1 Overview of North America Market
  7.2.2 U.S.
  7.2.3 Canada
  7.2.4 Mexico
7.3 European Market 2019-2030 by Country
  7.3.1 Overview of European Market
  7.3.2 Germany
  7.3.3 U.K.
  7.3.4 France
  7.3.5 Spain
  7.3.6 Italy
  7.3.7 Russia
  7.3.8 Rest of European Market
7.4 Asia-Pacific Market 2019-2030 by Country
  7.4.1 Overview of Asia-Pacific Market
  7.4.2 Japan
  7.4.3 China
  7.4.4 Australia
  7.4.5 India
  7.4.6 South Korea
  7.4.7 Rest of APAC Region
7.5 South America Market 2019-2030 by Country
  7.5.1 Argentina
  7.5.2 Brazil
  7.5.3 Chile
  7.5.4 Rest of South America Market
7.6 MEA Market 2019-2030 by Country
  7.6.1 Turkey
  7.6.2 Iran
  7.6.3 South Africa
  7.6.4 Other National Markets

8 COMPETITIVE LANDSCAPE

8.1 Overview of Key Vendors
8.2 New Product Launch, Partnership, Investment, and M&A
8.3 Company Profiles
AMEGA Biotech S.A.
Apotex Inc.
Biocon Ltd
Biogen Inc.
Boehringer Ingelheim
Celltrion, Inc.
Dr. Reddy’s Laboratories Ltd.
Eli Lilly and Company
Intas Pharmaceuticals Ltd.
LG Chem, Ltd.
Merck and Co. Inc.
Mylan N.V.
Pfizer Inc.
Samsung Biologics Co., Ltd.
Sandoz International GmbH
STADA Arzneimittel AG
Teva Pharmaceutical Industries Ltd.
RELATED REPORTS

List Of Tables

LIST OF TABLES:

Table 1. Snapshot of Global Biosimilars Market in Balanced Perspective, 2019-2030
Table 2. Growth Rate of World GDP, 2020-2022
Table 3. World Health Spending by Region, $ bn, 2013-2020
Table 4. Main Product Trends and Market Opportunities in Global Biosimilars Market
Table 5. Global Biosimilars Market by Product Type, 2019-2030, $ mn
Table 6. Global Biosimilars Market: Recombinant Non-glycosylated Biosimilars by Product, 2019-2030, $ mn
Table 7. Global Biosimilars Market: Recombinant Glycosylated Biosimilars by Product, 2019-2030, $ mn
Table 8. Global Biosimilars Market: Recombinant Peptides and Others by Product, 2019-2030, $ mn
Table 9. Global Biosimilars Market by Indication, 2019-2030, $ mn
Table 10. Global Biosimilars Market by Manufacturing, 2019-2030, $ mn
Table 11. Global Biosimilars Market by End User, 2019-2030, $ mn
Table 12. Global Biosimilars Market by Region, 2019-2030, $ mn
Table 13. Leading National Biosimilars Market, 2019 and 2030F, $ mn
Table 14. North America Biosimilars Market by Country, 2019-2030, $ mn
Table 15. U.S. Biosimilars Market by Product Type, 2019-2030, $ mn
Table 16. U.S. Biosimilars Market by Indication, 2019-2030, $ mn
Table 17. U.S. Biosimilars Market by End User, 2019-2030, $ mn
Table 18. FDA Approved Biosimilars in U.S., 2015-2020
Table 19. U.S. Select Pending Biosimilar BLAs as of December 2020
Table 20. U.S. Biosimilar Market Share (market share data through July 2020)
Table 21. Canada Biosimilars Market by Product Type, 2019-2030, $ mn
Table 22. Canada Biosimilars Market by Indication, 2019-2030, $ mn
Table 23. Canada Biosimilars Market by End User, 2019-2030, $ mn
Table 24. Mexico Biosimilars Market by Product Type, 2019-2030, $ mn
Table 25. Mexico Biosimilars Market by Indication, 2019-2030, $ mn
Table 26. Mexico Biosimilars Market by End User, 2019-2030, $ mn
Table 27. Europe Biosimilars Market by Country, 2019-2030, $ mn
Table 28. Approved Biosimilars in Europe
Table 29. Germany Biosimilars Market by Product Type, 2019-2030, $ mn
Table 30. Germany Biosimilars Market by Indication, 2019-2030, $ mn
Table 31. Germany Biosimilars Market by End User, 2019-2030, $ mn
Table 32. U.K. Biosimilars Market by Product Type, 2019-2030, $ mn
Table 33. U.K. Biosimilars Market by Indication, 2019-2030, $ mn
Table 34. U.K. Biosimilars Market by End User, 2019-2030, $ mn
Table 35. France Biosimilars Market by Product Type, 2019-2030, $ mn
Table 36. France Biosimilars Market by Indication, 2019-2030, $ mn
Table 37. France Biosimilars Market by End User, 2019-2030, $ mn
Table 38. Spain Biosimilars Market by Product Type, 2019-2030, $ mn
Table 39. Spain Biosimilars Market by Indication, 2019-2030, $ mn
Table 40. Spain Biosimilars Market by End User, 2019-2030, $ mn
Table 41. Italy Biosimilars Market by Product Type, 2019-2030, $ mn
Table 42. Italy Biosimilars Market by Indication, 2019-2030, $ mn
Table 43. Italy Biosimilars Market by End User, 2019-2030, $ mn
Table 44. Russia Biosimilars Market by Product Type, 2019-2030, $ mn
Table 45. Russia Biosimilars Market by Indication, 2019-2030, $ mn
Table 46. Russia Biosimilars Market by End User, 2019-2030, $ mn
Table 47. Biosimilars Market in Rest of Europe by Country, 2019-2030, $ mn
Table 48. APAC Biosimilars Market by Country, 2019-2030, $ mn
Table 49. Japan Biosimilars Market by Product Type, 2019-2030, $ mn
Table 50. Japan Biosimilars Market by Indication, 2019-2030, $ mn
Table 51. Japan Biosimilars Market by End User, 2019-2030, $ mn
Table 52. China Biosimilars Market by Product Type, 2019-2030, $ mn
Table 53. China Biosimilars Market by Indication, 2019-2030, $ mn
Table 54. China Biosimilars Market by End User, 2019-2030, $ mn
Table 55. Australia Biosimilars Market by Product Type, 2019-2030, $ mn
Table 56. Australia Biosimilars Market by Indication, 2019-2030, $ mn
Table 57. Australia Biosimilars Market by End User, 2019-2030, $ mn
Table 58. India Biosimilars Market by Product Type, 2019-2030, $ mn
Table 59. India Biosimilars Market by Indication, 2019-2030, $ mn
Table 60. India Biosimilars Market by End User, 2019-2030, $ mn
Table 61. South Korea Biosimilars Market by Product Type, 2019-2030, $ mn
Table 62. South Korea Biosimilars Market by Indication, 2019-2030, $ mn
Table 63. South Korea Biosimilars Market by End User, 2019-2030, $ mn
Table 64. Biosimilars Market in Rest of APAC by Country/Region, 2019-2030, $ mn
Table 65. South America Biosimilars Market by Country, 2019-2030, $ mn
Table 66. Argentina Biosimilars Market by Product Type, 2019-2030, $ mn
Table 67. Argentina Biosimilars Market by Indication, 2019-2030, $ mn
Table 68. Argentina Biosimilars Market by End User, 2019-2030, $ mn
Table 69. Brazil Biosimilars Market by Product Type, 2019-2030, $ mn
Table 70. Brazil Biosimilars Market by Indication, 2019-2030, $ mn
Table 71. Brazil Biosimilars Market by End User, 2019-2030, $ mn
Table 72. Chile Biosimilars Market by Product Type, 2019-2030, $ mn
Table 73. Chile Biosimilars Market by Indication, 2019-2030, $ mn
Table 74. Chile Biosimilars Market by End User, 2019-2030, $ mn
Table 75. MEA Biosimilars Market by Country, 2019-2030, $ mn
Table 76. Turkey Biosimilars Market by Product Type, 2019-2030, $ mn
Table 77. Turkey Biosimilars Market by Indication, 2019-2030, $ mn
Table 78. Turkey Biosimilars Market by End User, 2019-2030, $ mn
Table 79. Iran Biosimilars Market by Product Type, 2019-2030, $ mn
Table 80. Iran Biosimilars Market by Indication, 2019-2030, $ mn
Table 81. Iran Biosimilars Market by End User, 2019-2030, $ mn
Table 82. South Africa Biosimilars Market by Product Type, 2019-2030, $ mn
Table 83. South Africa Biosimilars Market by Indication, 2019-2030, $ mn
Table 84. South Africa Biosimilars Market by End User, 2019-2030, $ mn
Table 85. Breakdown of World Market by Key Vendor, 2020, %
Table 86. AMEGA Biotech S.A.: Company Snapshot
Table 87. AMEGA Biotech S.A.: Business Segmentation
Table 88. AMEGA Biotech S.A.: Product Portfolio
Table 89. AMEGA Biotech S.A.: Revenue, 2018-2020, $ mn

List Of Figures

LIST OF FIGURES:

Figure 1. Research Method Flow Chart
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 3. Global Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030
Figure 4. Global Biosimilars Market, 2019-2030, $ mn
Figure 5. EMA and FDA Biosimilar Approvals, 2015 - 2019
Figure 6. EMA-approved Biosimilars Distribution by Reference Product and Therapeutic Area
Figure 7. FDA-approved Biosimilars Distribution by Reference Product and Therapeutic Area
Figure 8. Impact of COVID-19 on Business
Figure 9. Primary Drivers and Impact Factors of Global Biosimilars Market
Figure 10. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million
Figure 11. World Population 65 and Over, % of Total Population, 1950-2060
Figure 12. Primary Restraints and Impact Factors of Global Biosimilars Market
Figure 13. Investment Opportunity Analysis
Figure 14. Porter’s Fiver Forces Analysis of Global Biosimilars Market
Figure 15. Breakdown of Global Biosimilars Market by Product Type, 2019-2030, % of Revenue
Figure 16. Global Addressable Market Cap in 2021-2030 by Product Type, Value ($ mn) and Share (%)
Figure 17. Global Biosimilars Market by Product Type: Recombinant Non-glycosylated Biosimilars, 2019-2030, $ mn
Figure 18. Global Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Insulin, 2019-2030, $ mn
Figure 19. Global Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Recombinant Human Growth Hormone (rHGH), 2019-2030, $ mn
Figure 20. Global Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Granulocyte Colony Stimulating Factor, 2019-2030, $ mn
Figure 21. Global Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Interferon, 2019-2030, $ mn
Figure 22. Global Biosimilars Market by Product Type: Recombinant Glycosylated Biosimilars, 2019-2030, $ mn
Figure 23. Global Biosimilars Market by Recombinant Glycosylated Biosimilars: Monoclonal Antibodies (mAb), 2019-2030, $ mn
Figure 24. Global Biosimilars Market by Recombinant Glycosylated Biosimilars: Erythropoietin (EPO), 2019-2030, $ mn
Figure 25. Global Biosimilars Market by Recombinant Glycosylated Biosimilars: Follicle Stimulating Hormone, 2019-2030, $ mn
Figure 26. Global Biosimilars Market by Product Type: Recombinant Peptides and Others, 2019-2030, $ mn
Figure 27. Global Biosimilars Market by Recombinant Peptides and Others: Tumor Necrosis Factor (TNF)-Inhibitor, 2019-2030, $ mn
Figure 28. Global Biosimilars Market by Recombinant Peptides and Others: Parathyroid Hormone, 2019-2030, $ mn
Figure 29. Global Biosimilars Market by Recombinant Peptides and Others: Enzymes, Immunomodulators, GnRH Analogs and Others, 2019-2030, $ mn
Figure 30. Breakdown of Global Biosimilars Market by Indication, 2019-2030, % of Sales Revenue
Figure 31. Global Addressable Market Cap in 2021-2030 by Indication, Value ($ mn) and Share (%)
Figure 32. Global Biosimilars Market by Indication: Cancer, 2019-2030, $ mn
Figure 33. Global Biosimilars Market by Indication: Autoimmune Disease, 2019-2030, $ mn
Figure 34. Global Biosimilars Market by Indication: Blood Disorder, 2019-2030, $ mn
Figure 35. Global Biosimilars Market by Indication: Diabetes, 2019-2030, $ mn
Figure 36. Global Biosimilars Market by Indication: Growth Hormone Deficiency, 2019-2030, $ mn
Figure 37. Global Biosimilars Market by Indication: Infectious Diseases, 2019-2030, $ mn
Figure 38. Global Biosimilars Market by Indication: Other Indications, 2019-2030, $ mn
Figure 39. Breakdown of Global Biosimilars Market by Manufacturing, 2019-2030, % of Sales Revenue
Figure 40. Global Addressable Market Cap in 2021-2030 by Manufacturing, Value ($ mn) and Share (%)
Figure 41. Global Biosimilars Market by Manufacturing: Contract Manufacturing, 2019-2030, $ mn
Figure 42. Global Biosimilars Market by Manufacturing: Inhouse Manufacturing, 2019-2030, $ mn
Figure 43. Breakdown of Global Biosimilars Market by End User, 2019-2030, % of Revenue
Figure 44. Global Addressable Market Cap in 2021-2030 by End User, Value ($ mn) and Share (%)
Figure 45. Global Biosimilars Market by End User: Hospitals and Clinics, 2019-2030, $ mn
Figure 46. Global Biosimilars Market by End User: Research Institutes, 2019-2030, $ mn
Figure 47. Global Biosimilars Market by End User: Other End Users, 2019-2030, $ mn
Figure 48. Global Market Snapshot by Region
Figure 49. Geographic Spread of Worldwide Biosimilars Market, 2019-2030, % of Sales Revenue
Figure 50. Global Addressable Market Cap in 2021-2030 by Region, Value ($ mn) and Share (%)
Figure 51. North American Biosimilars Market, 2019-2030, $ mn
Figure 52. Breakdown of North America Biosimilars Market by Country, 2019 and 2030, % of Revenue
Figure 53. Contribution to North America 2021-2030 Cumulative Market by Country, Value ($ mn) and Share (%)
Figure 54. U.S. Biosimilars Market, 2019-2030, $ mn
Figure 55. Biosimilar Approvals and Launches in U.S., 2015-2020
Figure 56. Canada Biosimilars Market, 2019-2030, $ mn
Figure 57. Biosimilars Market in Mexico, 2019-2030, $ mn
Figure 58. European Biosimilars Market, 2019-2030, $ mn
Figure 59. Breakdown of European Biosimilars Market by Country, 2019 and 2030, % of Revenue
Figure 60. Contribution to Europe 2021-2030 Cumulative Market by Country, Value ($ mn) and Share (%)
Figure 61. Biosimilars Market in Germany, 2019-2030, $ mn
Figure 62. Biosimilars Market in U.K., 2019-2030, $ mn
Figure 63. Biosimilars Market in France, 2019-2030, $ mn
Figure 64. Biosimilars Market in Spain, 2019-2030, $ mn
Figure 65. Biosimilars Market in Italy, 2019-2030, $ mn
Figure 66. Biosimilars Market in Russia, 2019-2030, $ mn
Figure 67. Biosimilars Market in Rest of Europe, 2019-2030, $ mn
Figure 68. Asia-Pacific Biosimilars Market, 2019-2030, $ mn
Figure 69. Breakdown of APAC Biosimilars Market by Country, 2019 and 2030, % of Revenue
Figure 70. Contribution to APAC 2021-2030 Cumulative Market by Country, Value ($ mn) and Share (%)
Figure 71. Biosimilars Market in Japan, 2019-2030, $ mn
Figure 72. Biosimilars Market in China, 2019-2030, $ mn
Figure 73. Biosimilars Market in Australia, 2019-2030, $ mn
Figure 74. Biosimilars Market in India, 2019-2030, $ mn
Figure 75. Biosimilars Market in South Korea, 2019-2030, $ mn
Figure 76. Biosimilars Market in Rest of APAC, 2019-2030, $ mn
Figure 77. South America Biosimilars Market, 2019-2030, $ mn
Figure 78. Breakdown of South America Biosimilars Market by Country, 2019 and 2030, % of Revenue
Figure 79. Contribution to South America 2021-2030 Cumulative Market by Country, Value ($ mn) and Share (%)
Figure 80. Biosimilars Market in Argentina, 2019-2030, $ mn
Figure 81. Biosimilars Market in Brazil, 2019-2030, $ mn
Figure 82. Biosimilars Market in Chile, 2019-2030, $ mn
Figure 83. Biosimilars Market in Rest of South America, 2019-2030, $ mn
Figure 84. Biosimilars Market in Middle East and Africa (MEA), 2019-2030, $ mn
Figure 85. Breakdown of MEA Biosimilars Market by Country, 2019 and 2030, % of Revenue
Figure 86. Contribution to MEA 2021-2030 Cumulative Market by Country, Value ($ mn) and Share (%)
Figure 87. Biosimilars Market in Turkey, 2019-2030, $ mn
Figure 88. Biosimilars Market in Iran, 2019-2030, $ mn
Figure 89. Biosimilars Market in South Africa, 2019-2030, $ mn
Figure 90. Growth Stage of Global Biosimilars Industry over the Forecast Period